Randomized trial: Immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls

Journal of Adolescent Health

Volumn 50, Issue 1, 2012, Pages 38-46

  Pedersen, Court ^a   Breindahl, Morten ^b   Aggarwal, Naresh ^c   Berglund, Johan ^d   Oroszlán, György ^e   Silfverdal, Sven Arne ^f   Szts, Péter ^g   O'Mahony, Michael ^h   David, Marie Pierre ⁱ   Dobbelaere, Kurt ⁱ   Dubin, Gary ^j   Descamps, Dominique ⁱ  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Aggarwal and Associates Ltd   (Canada)

^d BLEKINGE INSTITUTE OF TECHNOLOGY   (Sweden)

^e Nukleáris Medicina Osztály   (Hungary)

^f UMEÅ UNIVERSITY   (Sweden)

^g Erzsebet Hospital   (Hungary)

^h Hódmezovásárhely ^*  (Canada)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Adolescent; Adverse effects; Female; Hepatitis A vaccines; Hepatitis B vaccines; Human papillomavirus vaccines; Immunogenicity; Randomized controlled trial

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALUMINUM HYDROXIDE; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SAFETY; UTERINE CERVICAL NEOPLASMS;

EID: 84055218378     PISSN: 1054139X     EISSN: 18791972     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2011.10.009     Document Type: Article

References (37)

1. C. Pedersen, T. Petaja, G. Strauss Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant J Adolesc Health 40 2007 564 571 (Pubitemid 46771257)
2. D. Descamps, K. Hardt, B. Spiessens Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials Hum Vaccin 5 2009 332 340
3. J. Paavonen, D. Jenkins, F.X. Bosch Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2007 2161 2170 (Pubitemid 46977438)
4. J. Paavonen, P. Naud, J. Salmerón Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
5. D.M. Harper, E.L. Franco, C. Wheeler Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial Lancet 364 2004 1757 1765 (Pubitemid 39488060)
6. D.M. Harper, E.L. Franco, C.M. Wheeler Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial Lancet 367 2006 1247 1255
7. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years Lancet 374 2009 1975 1985
8. P. Van Damme, G. Leroux-Roels, B. Law Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults J Med Virol 65 2001 6 13
9. Z. Kurugöl, F. Mutluba, T. Ozacar A two-dose schedule for combined hepatitis A and B vaccination in children aged 615 years Vaccine 23 2005 2876 2880 (Pubitemid 40386489)
10. National Advisory Committee on Immunization (NACI) Canadian Immunization Guide. Public Health Agency of Canada. 7th edition. 2006 [Online] http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006-e.pdf Accessed September 30, 2011
11. National Health and Medical Research Council (NHMRC) The Australian Immunisation Handbook. 9th edition. 2008 [Online] http://immunise.health.gov.au/ internet/immunise/publishing.nsf/Content/Handbook-home Accessed September 30, 2011
12. Twinrix Paediatric Vaccine Summary of Product Characteristics [Online] http://emc.medicines.org.uk/medicine/2062/SPC/Twinrix+Paediatric+Vaccine/ Accessed September 30, 2011
13. D.L. Murdoch, K. Goa, D.P. Figgitt Combined hepatitis A and B vaccines: A review of their immunogenicity and tolerability Drugs 63 2003 2625 2649 (Pubitemid 37491565)
14. Public Health Agency of Canada Recommendations on a Human Papillomavirus Immunization Program [Online] http://www.phac-aspc.gc.ca/publicat/2008/ papillomavirus-papillome/papillomavirus-papillome-11-eng.php Accessed September 30, 2011
15. P. Cambron, J.M. Jacquet, B. Hoet, M. Lievens Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine Clin Vaccine Immunol 16 2009 1236 1246
16. F.J. Dessy, S.L. Giannini, C.A. Bougelet Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine Hum Vaccin 4 2008 425 434
17. E.E. Mast, H.S. Margolis, A.E. Fiore A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents MMWR Recomm Rep 54 2005 1 31
18. T. Petaja, C. Pedersen, A. Poder Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women Int J Cancer 129 2011 2147 2157
19. W. Szmuness, C.E. Stevens, E.J. Harley Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States N Engl J Med 303 1980 833 841 (Pubitemid 10014927)
20. D.P. Francis, S.C. Hadler, S.E. Thompson The prevention of hepatitis B with vaccine Report of the centers for disease control multi-center efficacy trial among homosexual men Ann Intern Med 97 1982 362 366 (Pubitemid 12061584)
21. S.C. Hadler, D.P. Francis, J.E. Maynard Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men N Engl J Med 315 1986 209 214 (Pubitemid 16097121)
22. A.D. Jack, A.J. Hall, N. Maine What level of hepatitis B antibody is protective? J Infect Dis 179 1999 489 492 (Pubitemid 29086654)
23. C.M. Wheeler, O.M. Bautista, J.E. Tomassini Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines Vaccine 26 2008 686 696
24. G. Leroux-Roels, E. Haelterman, C. Maes Randomized trial of the immunogenicity and safety of the hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine Clin Vaccine Immunol 18 2011 1510 1518
25. Schmeink CE. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls. Vaccine (in press).
26. K. Levie, J. Beran, F. Collard, C. Nguyen Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 1215 years Vaccine 20 2002 2579 2584 (Pubitemid 34615598)
27. G. Leroux-Roels, B. Abraham, M. Fourneau A comparison of two commercial recombinant vaccines for hepatitis B in adolescents Vaccine 19 2000 937 942
28. J. Zuckerman, J. van Hattum, M. Cafferkey Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infect Dis 7 2007 410 419 (Pubitemid 46779095)
29. C.O. Mackie, J.A. Buxton, S. Tadwalkar, D.M. Patrick Hepatitis B immunization strategies: Timing is everything CMAJ 180 2009 196 202
30. World Health Organization WHO Vaccine Preventable Diseases Monitoring System: 2011 Global Summary http://apps.who.int/immunization-monitoring/en/ globalsummary/countryprofileselect.cfm Accessed September 30, 2011
31. F. Diaz-Mitoma, B. Law, A. Subramanya, B. Hoet Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents Vaccine 26 2008 1759 1763
32. K. Van Herck, G. Leroux-Roels, P. Van Damme Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults Travel Med Infect Dis 5 2007 171 175 (Pubitemid 46585955)
33. N. De Carvalho, J. Teixeira, C.M. Roteli-Martins Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women Vaccine 28 2010 6247 6255
34. P. Naud, C.M. Roteli-Martins, N. De Carvalho et al. HPV-16/18 vaccine: Sustained immunogenicity and efficacy up to 9.4 years 27th International Papillomavirus Conference and Clinical Workshop, Berl, Germany 2011, Sept 1722 http://www.hpv2011.org/pics/1/4/Abstract%20Book%202%20APSC%20WEBB%20110922.pdf Accessed September 30, 2011
35. P. Van Damme, M. Van der Wielen Combining hepatitis A and B vaccination in children and adolescents Vaccine 19 2001 2407 2412 (Pubitemid 32234250)
36. J. Garcia-Sicilia, T.F. Schwarz, A. Carmona Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women J Adolesc Health 46 2010 142 151
37. Wheeler CM, Harvey B, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine co-administered with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls aged 1118 years: Results from a randomized open trial. Pediatr Infect Dis J (in press).